Global Cystic Fibrosis Market Analysis & Forecast 2017 To 2023

Cystic fibrosis is a chronic, genetic disease which affects the productivity of the body leading to severe disability and early death.

Reference: 180087
Price: $4,450.00
Tax included

General

Publisher:
Market Research Future
Geography Covered
Global
Publication Date
Sep. 2017
Pages
68
Version:
2017
Language
  • English
  • Chinese
Format
License

Introduction:
Cystic fibrosis is a chronic, genetic disease which affects the productivity of the body leading to severe disability and early death. Symptoms of cystic fibrosis include frequent lung infections, diarrhea, and poor growth of the body. The global cystic fibrosis market is expected to reach USD 8852.2 million by 2022 at a CAGR of 13.5% during the forecast period.
The global cystic fibrosis market is segmented on the basis of treatment method which includes Medication, Devices and Other Treatments. Medicines capture the maximum share in the cystic fibrosis market. Medication segment accounted market share in all the regions across the global
On the basis of region, the market is segmented into four major regions namely North America, Europe, Asia-Pacific and Middle East & Africa. North America accounted for the largest market share in the global cystic fibrosis market while Asia pacific is the fastest growing region in this market.
Key Players:
The leading market players in the global cystic fibrosis market include AbbVie, Allergan Plc., Chiesi Farmaceutici S.p.A., F. Hoffmann-La Roche AG, Gilead Sciences, Novartis AG, Pharmaxis Ltd., PTC Therapeutics, and Vertex Pharmaceuticals Incorporated.
Study objectives of cystic fibrosis market:
 To provide insights about factors influencing and affecting the market growth
 To provide historical and forecast revenues of the market segments and sub-segments with respect to regional and country-level markets
 To provide historical and forecast revenue of the market segments based on types, products, applications, end users, and its sub-segments.
 To provide strategic profiling of key players in the market, comprehensively analyzing their market share, core competencies, and drawing a competitive landscape for the market


Target Audience:
• Pharmaceutical companies
• Hospitals & Clinics
• Potential investors
• Key executive (CEO and COO) and strategy growth manager

Key Findings:
• The global market for cystic fibrosis is expected to reach USD 8852.2 million by 2022 from USD 3652.2 million in 2016.
• Americas commands largest market share in 2016, it is expected to reach USD 3882.5 million by 2022.
• Asia-Pacific registers fastest growing CAGR of 13.5% during the forecast period from 2017-2022.
The reports also cover country level analysis:
• America
• North America
• US
• Canada
• Latin America
• Europe
• Western Europe
• Germany
• France
• UK
• Italy
• Spain
• Rest Of Western Europe
• Eastern Europe
• Asia-Pacific
• Australia
• Japan
• China
• India
• Republic of Korea
• Rest of Asia-Pacific
• Middle East & Africa
• Middle East
• Africa

Table of Contents

1 Introduction
1.1 Definition
1.2 Scope of Study
1.3 Research Objective
1.4 Assumptions & Limitations
1.4.1 Assumptions
1.4.2 Limitations
1.5 Market Structure
2 Research Methodology
2.1 Research Process
2.2 Primary Research
2.3 Secondary Research
3 Market Dynamics
3.1 Drivers
3.1.1 Introduction
3.1.2 Development of New Drugs and Therapies
3.1.3 Financial Support from CFF in Research and Development of CF Drugs
3.2 Restraints
3.2.1 Introduction
3.2.2 High Cost of the Drugs and Treatment
3.3 Opportunities
3.4 Challenges
3.4.1 Awareness about the Rare Disease in the Developing Countries
4 Market Factor Analysis
4.1 Porter’s Five Forces Model
4.1.1 Bargaining Power of Suppliers
4.1.2 Bargaining Power of Buyers
4.1.3 Threat of New Entrants
4.1.4 Threat of Substitutes
4.1.5 Intensity of Rivalry
5 Cystic Fibrosis Market, By Treatment Method
5.1 Introduction
5.2 Medication
5.3 Devices
5.4 Other Treatments
6 Cystic Fibrosis Market, By Regions
6.1 Introduction
6.2 North America
6.3 Europe
6.4 Asia-Pacific
6.5 Middle East & Africa
7 Company Share Analysis
8 Company Profile
8.1 AbbVie
8.1.1 Company Overview
8.1.2 Product Overview
8.1.3 Financials
8.1.4 Key Developments
8.2 Allergan Plc
8.2.1 Company Overview
8.2.2 Product Overview
8.2.3 Financials
8.2.4 Key Developments
8.3 Chiesi Farmaceutici S.p.A.
8.3.1 Company Overview
8.3.2 Product/Business Segment Overview
8.3.3 Financials
8.3.4 Key Developments
8.4 F. Hoffmann-La Roche AG
8.4.1 Company Overview
8.4.2 Product/Business Segment Overview
8.4.3 Financials
8.4.4 Key Developments
8.5 Gilead Sciences
8.5.1 Company Overview
8.5.2 Product Overview
8.5.3 Financials
8.5.4 Key Developments
8.6 Novartis AG
8.6.1 Company Overview
8.6.2 Product Overview
8.6.3 Financials
8.6.4 Key Developments
8.7 Pharmaxis Ltd.
8.7.1 Company Overview
8.7.2 Product Overview
8.7.3 Financials
8.7.4 Key Developments
8.8 PTC Therapeutics
8.8.1 Company Overview
8.8.2 Product Overview
8.8.3 Financials
8.8.4 Key Developments
8.9 Vertex Pharmaceuticals Incorporated
8.9.1 Company Overview
8.9.2 Product/Business Segment Overview
8.9.3 Financials
8.9.4 Key Developments

TABLE 1 GLOBAL CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2013-2022 ($MILLION)
TABLE 2 GLOBAL CYSTIC FIBROSIS MEDICATION MARKET, BY REGION, 2013-2027 ($MILLION)
TABLE 3 GLOBAL CYSTIC FIBROSIS DEVICES MARKET, BY REGION, 2013-2027 ($MILLION)
TABLE 4 GLOBAL CYSTIC FIBROSIS OTHER TREATMENTS MARKET, BY REGION, 2013-2027 ($MILLION)
TABLE 5 GLOBAL CYSTIC FIBROSIS MARKET, BY REGION, 2013-2022 ($MILLION)
TABLE 6 NORTH AMERICA CYSTIC FIBROSIS MARKET, BY COUNTRY, 2013-2022 ($MILLION)
TABLE 7 NORTH AMERICA CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2013-2022 ($MILLION)
TABLE 8 U.S. CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2013-2022 ($MILLION)
TABLE 9 CANADA CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2013-2022 ($MILLION)
TABLE 10 EUROPE CYSTIC FIBROSIS MARKET, BY COUNTRY, 2013-2022 ($MILLION)
TABLE 11 EUROPE CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2013-2022 ($MILLION)
TABLE 12 GERMANY CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2013-2022 ($MILLION)
TABLE 13 FRANCE CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2013-2022 ($MILLION)
TABLE 14 U.K. CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2013-2022 ($MILLION)
TABLE 15 ITALY CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2013-2022 ($MILLION)
TABLE 16 SPAIN CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2013-2022 ($MILLION)
TABLE 17 REST OF WESTERN EUROPE CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2013-2022 ($MILLION)
TABLE 18 EASTERN EUROPE CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2013-2022 ($MILLION)
TABLE 19 ASIA-PACIFIC CYSTIC FIBROSIS MARKET, BY COUNTRY, 2013-2022 ($MILLION)
TABLE 20 ASIA-PACIFIC CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2013-2022 ($MILLION)
TABLE 21 AUSTRALIA CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2013-2022 ($MILLION)
TABLE 22 JAPAN CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2013-2022 ($MILLION)
TABLE 23 CHINA CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2013-2022 ($MILLION)
TABLE 24 INDIA CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2013-2022 ($MILLION)
TABLE 25 REPUBLIC OF KOREA CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2013-2022 ($MILLION)
TABLE 26 REST OF ASIA-PACIFIC CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2013-2022 ($MILLION)
TABLE 27 MIDDLE EAST & AFRICA CYSTIC FIBROSIS MARKET, BY REGION, 2013-2022 ($MILLION)
TABLE 28 MIDDLE EAST & AFRICA CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2013-2022 ($MILLION)
TABLE 29 MIDDLE EAST CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2013-2022 ($MILLION)
TABLE 30 AFRICA CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2013-2022 ($MILLION)
TABLE 31 CHIESI FARMACEUTICI S.P.A.: KEY DEVELOPMENTS
TABLE 32 VERTEX PHARMACEUTICALS INCORPORATED: KEY DEVELOPMENTS

FIGURE 1 RESEARCH PROCESS OF MRFR
FIGURE 2 PORTER'S 5 FORCES ANALYSIS OF GLOBAL CYSTIC FIBROSIS MARKET
FIGURE 3 GLOBAL CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2015 & 2022 ($MILLION)
FIGURE 4 GLOBAL CYSTIC FIBROSIS MARKET, BY REGION, 2015 (%)
FIGURE 5 NORTH AMERICA CYSTIC FIBROSIS MARKET, BY COUNTRY, 2015 (%)
FIGURE 6 NORTH AMERICA CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2015 & 2022 ($MILLION)
FIGURE 7 EUROPE CYSTIC FIBROSIS MARKET, BY COUNTRY, 2015 (%)
FIGURE 8 EUROPE CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2015 & 2022 ($MILLION)
FIGURE 9 ASIA-PACIFIC CYSTIC FIBROSIS MARKET, BY COUNTRY, 2015 (%)
FIGURE 10 ASIA-PACIFIC CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2015 % 2022 ($MILLION)
FIGURE 11 MIDDLE EAST & AFRICA CYSTIC FIBROSIS MARKET, BY REGION, 2015 (%)
FIGURE 12 MIDDLE EAST & AFRICA CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2015 & 2022 ($MILLION)
FIGURE 13 CYSTIC FINROSIS MARKET SHARE, 2016 (%)
FIGURE 14 ABBVIE: RECENT FINANCIAL
FIGURE 15 ABBVIE: BUSINESS REVENUE, 2015 (%)
FIGURE 16 ABBVIE: GEOGRAPHIC REVENUE, 2015 (%)
FIGURE 17 ALLERGAN: RECENT FINANCIAL
FIGURE 18 ALLERGAN: BUSINESS REVENUE, 2015 (%)
FIGURE 19 ALLERGAN: GEOGRAPHIC REVENUE, 2015 (%)
FIGURE 20 CHIESI FARMACEUTICI S.P.A.: RECENT FINANCIALS
FIGURE 21 F. HOFFMANN-LA ROCHE AG.: RECENT FINANCIALS
FIGURE 22 F. HOFFMANN-LA ROCHE AG.: BUSINESS REVENUE
FIGURE 23 GILEAD SCIENCES: RECENT FINANCIAL
FIGURE 24 NOVARTIS AG: RECENT FINANCIALS
FIGURE 25 NOVARTIS AG: BUSINESS REVENUE, 2015 (%)
FIGURE 26 NOVARTIS AG: GEOGRAPHIC REVENUE, 2015 (%)
FIGURE 27 PHARMAXIS LTD: RECENT FINANCIALS
FIGURE 28 PTC THERAPEUTICS: RECENT FINANCIALS
FIGURE 29 PTC THERAPEUTICS: GEOGRAPHICAL REVENUE (%)
FIGURE 30 PTC THERAPEUTICS: R&D EXPENSES, 2015 (%)
FIGURE 31 VERTEX PHARMACEUTICALS INCORPORATED: RECENT FINANCIALS
FIGURE 32 VERTEX PHARMACEUTICALS INCORPORATED: BUSINESS REVENUE
FIGURE 33 VERTEX PHARMACEUTICALS INCORPORATED: GEOGRAPHICAL REVENUE

Scroll